This course has expired. View available courses.
Oncology
The Evolving Role of Immunotherapy in Mesothelioma and Metastatic NSCLC
Immunotherapies have made important advancements in oncology by expanding treatment options and demonstrating clinical benefits across many different cancer types.
For metastatic non-small cell lung cancer (NSCLC), treatments are evolving and the options available are increasing with the release of key clinical trial results. PD-L1 is a widely validated biomarker assay, which serves as a therapeutic target in this cancer type.
For previously untreated unresectable Malignant Pleural Mesothelioma (MPM), nivolumab plus ipilimumab is the only immunotherapy treatment approved by Health Canada.
This program explores the benefits and limitations of immunotherapy treatment options as well as theimportant clinical trials that have helped to guide their use in the management of metastatic NSCLC and MPM.
This program has received an educational grant or in-kind support from BMS.
DURATION
1 hr
PROFESSION
Specialist
# OF CREDITS
3
ACCREDITATION
MOC - Section 3
EXPIRY DATE
2022-06-03
Immunotherapies have made important advancements in oncology by expanding treatment options and demonstrating clinical benefits across many different cancer types.
For metastatic non-small cell lung cancer (NSCLC), treatments are evolving and the options available are increasing with the release of key clinical trial results. PD-L1 is a widely validated biomarker assay, which serves as a therapeutic target in this cancer type.
For previously untreated unresectable Malignant Pleural Mesothelioma (MPM), nivolumab plus ipilimumab is the only immunotherapy treatment approved by Health Canada.
This program explores the benefits and limitations of immunotherapy treatment options as well as theimportant clinical trials that have helped to guide their use in the management of metastatic NSCLC and MPM.
This program has received an educational grant or in-kind support from BMS.
Faculty
Penelope Bradbury, MB, BCh, FRACP, MD (UK)
Parneet Cheema, MD, MBiotech, FRCPC
Barbara Melosky, MD, FRCP(C)
Solange Peters, MD, PhD
Learning objectives
After viewing this expert Webinar, participants will be better able to:
- Discuss the changing role of immunotherapy in the management of metastatic non-small cell lung cancer (NSCLC)
- Assess the role of immunotherapy in the malignant pleural mesothelioma (MPM) patient pathway
- Determine the role of combining immunotherapies for individuals with NSCLC or MPM
Accreditation
Credits for Royal College Specialists:
This event is an Accredited Self-Assessment program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by Queen's University Office of CPD. You may claim a maximum of 1 hour (credits are automatically calculated). Session ID: 00013653
Credits for Health Professionals:
This is an accredited learning activity which provided up to 1 hour of Continuing Education.
This program has been developed in collaboration with the CPD Network Association and OncologyEducation.